LON:OXB Oxford Biomedica (OXB) Share Forecast, Price & News GBX 300 -7.00 (-2.28%) (As of 04:45 PM ET) Add Compare Share Share Today's Range 297▼ 30850-Day Range 240▼ 451.5052-Week Range 236.50▼ 575Volume113,653 shsAverage Volume122,098 shsMarket Capitalization£289.80 millionP/E RatioN/ADividend YieldN/APrice TargetGBX 605 ProfileProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlinesProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines Oxford Biomedica MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside103.0% UpsideGBX 605 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares£10.19 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 stars 3.2 Analyst's Opinion Consensus RatingOxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 605, Oxford Biomedica has a forecasted upside of 103.0% from its current price of GBX 298.Amount of Analyst CoverageOxford Biomedica has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for OXB. Previous Next 0.0 Dividend Strength Dividend YieldOxford Biomedica does not currently pay a dividend.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for OXB. Previous Next 2.3 News and Social Media Coverage News SentimentOxford Biomedica has a news sentiment score of 0.09. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oxford Biomedica this week, compared to 0 articles on an average week.MarketBeat Follows7 people have added Oxford Biomedica to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought £101,906.20 in company stock and sold GBX 0 in company stock.Percentage Held by InsidersOnly 8.68% of the stock of Oxford Biomedica is held by insiders.Percentage Held by Institutions67.05% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -451.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -451.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 1.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oxford Biomedica (LON:OXB) StockOxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its s LentiVector platform technology is an advanced lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems. The company operates in two segments, Platform and Product. The Platform segment engages in bioprocessing and process development activities for third parties. The Product segment is involved in the research and development of new gene therapeutic product candidates. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, and adenoviral vectors. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.Read More OXB Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart OXB Stock News HeadlinesOctober 4, 2023 | americanbankingnews.comOxford Biomedica (LON:OXB) Stock Price Crosses Below 200 Day Moving Average of $398.85September 27, 2023 | americanbankingnews.comOxford Biomedica (LON:OXB) Price Target Cut to GBX 310 by Analysts at Liberum CapitalOctober 4, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 27, 2023 | americanbankingnews.comOxford Biomedica plc (LON:OXB) Insider Dame Kay Davies Acquires 1,000 SharesSeptember 22, 2023 | finance.yahoo.comOxford Biomedica First Half 2023 Earnings: Misses ExpectationsSeptember 20, 2023 | finance.yahoo.comOxford BioMedica shares soar as vaccine maker raises earnings guidanceJuly 18, 2023 | finance.yahoo.comOxford Biomedica Implements Sapio Sciences' Electronic Laboratory NotebookMay 25, 2023 | msn.comRBC Capital Markets Reiterates Oxford Biomedica (LSE:OXB) Outperform RecommendationOctober 4, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.May 15, 2023 | finance.yahoo.comOxford Biomedica launches TetraVecta - the next generation lentiviral vector systemMay 5, 2023 | finance.yahoo.comWhy Investors Shouldn't Be Surprised By Oxford Biomedica plc's (LON:OXB) Low P/SApril 26, 2023 | finance.yahoo.comOxford Biomedica Appoints Leone Patterson as Non-Executive DirectorApril 25, 2023 | markets.businessinsider.comOxford Biomedica Posts FY LossApril 21, 2023 | marketwatch.com2023-2030 "CGT CDMO Market" Share | Global Industry Analysis and ForecastApril 12, 2023 | marketwatch.com2023-2030 Global CGT CDMO Market is Growing Rapidly with Modern TrendMarch 26, 2023 | marketwatch.comCGT CDMO Market Share and Forecast till 2030March 15, 2023 | benzinga.comOxford BioMedica Stock (OTC:OXBDF), Quotes and News SummaryMarch 11, 2023 | finance.yahoo.comAs Oxford Biomedica plc's market cap (LON:OXB) drops to UK£484m, insiders might be questioning their decision to buy earlier this yearFebruary 25, 2023 | marketwatch.comWhat is a CAGR of CGT CDMO Market? CGT CDMO Market Value in 2028 with Competition Analysis Data of Top Key PlayersFebruary 22, 2023 | marketwatch.comCGT CDMO Market Size Global Research Report, 2023 - 2028January 30, 2023 | marketwatch.comCGT CDMO Market Size 2023 Trend and Opportunities, Analysis, CAGR and Value Chain Study, Business Growth to 2028January 20, 2023 | marketwatch.comCGT CDMO Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028January 12, 2023 | marketwatch.comCGT CDMO Market Present Development Scenario and Growth Prospects to help you understand the Implications for Your Business | Newest 112 InsightsJanuary 1, 2023 | finance.yahoo.comA Look At The Intrinsic Value Of Oxford Biomedica plc (LON:OXB)December 14, 2022 | yahoo.comOxford Biomedica Solutions forms new partnerships with three biotechnology companiesDecember 9, 2022 | marketwatch.comCGT CDMO Market 2022 : Incredible Possibilities, Growth Analysis and Forecast To 2028November 22, 2022 | finance.yahoo.comOxford Biomedica Appoints Dr Frank Mathias as Chief Executive OfficerSee More Headlines Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:OXB CUSIPN/A CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees894Year FoundedN/APrice Target and Rating Average Stock Price ForecastGBX 605 High Stock Price ForecastGBX 1,010 Low Stock Price ForecastGBX 310 Forecasted Upside/Downside+103.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)GBX (0.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-61,630,000.00 Net Margins-51.78% Pretax MarginN/A Return on Equity-30.64% Return on Assets-12.05% Debt Debt-to-Equity Ratio57.10 Current Ratio3.32 Quick Ratio1.67 Sales & Book Value Annual Sales£119.02 million Price / Sales2.42 Cash FlowGBX 99.12 per share Price / Cash Flow3.01 Book ValueGBX 178 per share Price / Book1.67Miscellaneous Outstanding Shares96,600,000Free FloatN/AMarket Cap£287.87 million OptionableNot Optionable Beta1.03 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Stuart Paynter (Age 49)CFO, Company Sec. & Director Comp: $832kDr. Frank Mathias (Age 61)CEO & Director Mr. Nick PageChief Operations OfficerDr. James Miskin Ph.D.Chief Technical OfficerDr. Kyriacos Mitrophanous Ph.D.Chief Scientific OfficerMr. Matthew TreagusChief Information Officer & Chief of StaffSophia BolhassanHead of Investor RelationsMs. Natalie Louise WalterGen. CounselMs. Lisa JamesChief People OfficerMs. Sarah MacleodHead of CommunicationsMore ExecutivesKey CompetitorsHorizon Discovery Group plc (HZD.L)LON:HZDAvacta GroupLON:AVCTVerona Pharma plc (VRP.L)LON:VRPFaron Pharmaceuticals OyLON:FARNBioventixLON:BVXPView All CompetitorsInsidersDame Kay DaviesBought 1,000 shares on 9/26/2023Total: £291,000.00 ($291.00/share)Roch DoliveuxBought 36,130 shares on 9/20/2023Total: £9.90 M ($274.00/share)Catherine MoukheibirBought 6,684 shares on 7/3/2023Total: £2.87 M ($430.00/share)Catherine MoukheibirBought 8,910 shares on 10/11/2022Total: £2.82 M ($317.00/share)View All Insider Transactions OXB Stock - Frequently Asked Questions Should I buy or sell Oxford Biomedica stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oxford Biomedica in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" OXB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OXB, but not buy additional shares or sell existing shares. View OXB analyst ratings or view top-rated stocks. What is Oxford Biomedica's stock price forecast for 2023? 3 analysts have issued 1 year target prices for Oxford Biomedica's shares. Their OXB share price forecasts range from GBX 310 to GBX 1,010. On average, they expect the company's stock price to reach GBX 605 in the next twelve months. This suggests a possible upside of 103.0% from the stock's current price. View analysts price targets for OXB or view top-rated stocks among Wall Street analysts. How have OXB shares performed in 2023? Oxford Biomedica's stock was trading at GBX 442.50 at the beginning of the year. Since then, OXB shares have decreased by 32.7% and is now trading at GBX 298. View the best growth stocks for 2023 here. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford Biomedica (OXBDF), Premier Oil (PMO), AFR.L (AFR), Barclays (BARC) and Genel Energy (GENL). What is Oxford Biomedica's stock symbol? Oxford Biomedica trades on the London Stock Exchange (LON) under the ticker symbol "OXB." How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Oxford Biomedica's stock price today? One share of OXB stock can currently be purchased for approximately GBX 298. How much money does Oxford Biomedica make? Oxford Biomedica (LON:OXB) has a market capitalization of £287.87 million and generates £119.02 million in revenue each year. The biopharmaceutical company earns £-61,630,000.00 in net income (profit) each year or GBX (0.66) on an earnings per share basis. How many employees does Oxford Biomedica have? The company employs 894 workers across the globe. How can I contact Oxford Biomedica? Oxford Biomedica's mailing address is Windrush Court, Transport Way, OXFORD, OX4 6LT, United Kingdom. The official website for the company is www.oxfordbiomedica.co.uk. The biopharmaceutical company can be reached via phone at +44-1865-783000. This page (LON:OXB) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.